Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
posdinemab (JNJ-63733657) / J&J
2020-000116-30: A Clinical Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease	Not yet recruiting	2	420	Europe	JNJ-63733657, JNJ-63733657, Solution for infusion	Janssen-Cilag International NV, Janssen Research & Development, LLC	Early Alzheimer’s Disease, Early Alzheimer’s Disease, Diseases [C] - Nervous System Diseases [C10]
Autonomy, NCT04619420: A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Active, not recruiting	2	523	Europe, Canada, Japan, US, RoW	JNJ-63733657, Placebo	Janssen Research & Development, LLC	Alzheimer Disease, Cognitive Dysfunction, Dementia	02/26	12/32